BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts

BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts

The therapeutic landscape of melanoma is improving rapidly. Targeted inhibitors show promising results, but drug resistance often limits durable clinical responses. There is a need for in vivo systems that allow for mechanistic drug resistance studies and (combinatorial) treatment optimization. Ther...

Full description

Bibliographic Details
Main Authors: Kemper, Kristel, Krijgsman, Oscar, Kong, Xiangjun, Cornelissen-Steijger, Paulien, Shahrabi, Aida, Weeber, Fleur, van der Velden, Daphne L., Bleijerveld, Onno B., Kuilman, Thomas, Kluin, Roel J.C., Sun, Chong, Voest, Emile E., Ju, Young Seok, Schumacher, Ton N.M., Altelaar, A.F. Maarten, McDermott, Ultan, Adams, David J., Blank, Christian U., Haanen, John B., Peeper, Daniel S.
Format: Online
Language:English
Published: Cell Press 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929150/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929150/

Similar Items